Log in

Leukemia & Lymphoma Society Commits $6 Million to MDS Treatment

August 13, 2019 10:26 AM | Philanthropy Delaware (Administrator)

 (August 10 2019, PND by Candid) Forty Seven, Inc., a clinical-stage immuno-oncology company, has announced funding commitments totaling up to $6 million from the Leukemia & Lymphoma Society to advance the development of a treatment for myelodysplastic syndromes (MDS).

Awarded through LLS's Therapy Acceleration Program (TAP), the company will receive up to $3 million to accelerate the development of 5F9 for the treatment of MDS, contingent on the achievement of certain clinical or regulatory milestones. 5F9 is a monoclonal antibody against CD47 that is designed to interfere with recognition of CD47 by the SIRPĪ± receptor on macrophages, locking the "don't eat me" signal used by cancer cells to avoid being ingested by the latter.

For the complete article from Candid click here.

Copyright Philanthropy Delaware, Inc. 2017
Philanthropy Delaware, Inc. is a 501(c)3 nonprofit organization

Contact Us:
Office: (302) 588-1342

100 W. 10th Street, Suite 500
Wilmington, DE 19801

Powered by Wild Apricot Membership Software